A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy

Ikuko Hirai, Keiji Tanese, Shoko Obata, Takeru Funakoshi

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Primary malignant melanoma of the lung (PMML) is an exceedingly rare type of melanoma. Here, we report a case of an 86-year-old Japanese woman who was diagnosed as PMML with subcarinal lymph node metastasis. She was treated with intravenous administration of programmed cell death-1 (PD-1) inhibitor, nivolumab. After the treatment, lymph node lesion regressed. The size of primary lesion was also controlled in combination with radiotherapy. In this case, two histological features were noted in the biopsy specimen that supported a response to nivolumab: membranous expression of programmed death ligand-1 (PD-L1) in tumor cells and dense scattered infiltration of CD8+ TILs. The clinical course of this case suggests that certain PMML cases may also respond to anti-PD-1 therapy.

Original languageEnglish
Pages (from-to)173-175
Number of pages3
JournalIndian Journal of Thoracic and Cardiovascular Surgery
Volume33
Issue number2
DOIs
Publication statusPublished - 2017 Jun 1

Keywords

  • Primary malignant melanoma of the lung
  • Programmed cell death 1(PD-1)
  • Tumor infiltrating lymphocytes (TIL)

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'A case of primary malignant melanoma of the lung responded to anti-PD-1 antibody therapy'. Together they form a unique fingerprint.

Cite this